Raise the Bar—Direct, Real-Time Proof That Your Cancer Therapy Works.
Our first-in-class granzyme B radiodiagnostic PET scan[III]“First-in-class” qualifier. “First-in-class” reflects CytoSite Bio’s good-faith assessment of publicly available information regarding granzyme B–targeted radiopharmaceutical imaging as of the page’s publication date and may not capture all global research activities. represents a paradigm shift in clinical trial assessment. Unlike traditional metabolic or anatomical scans, our investigational CSB-321 PET tracer measures the immune system’s real-time activity[IV]Biomarker / imaging purpose. Statements referring to “early mechanistic insights” or “real-time activity” describe investigational imaging endpoints that assess signals consistent with immune engagement. These measures are not, by themselves, diagnostic of clinical benefit, and are not intended to replace standard-of-care assessments. at all tumor sites,[V]Site-level signal, not whole-patient outcome. CSB-321 PET aims to visualize signal at lesion sites consistent with immune engagement. Signal presence, absence, or change at a given site may not reflect overall patient response or long-term outcomes. providing an early mechanistic assessment of a drug within days.[VI]Timing claims. References to “within days” or “as early as 14 days” reflect observations in early studies with specific protocols. Actual timing, thresholds, and interpretability vary by indication, therapy, and study design. Early functional evidence of treatment engagement—showing which tumors are active and how they change over time—could enable swift go/no-go decisions, accelerated clinical timelines, and de-risking of pipelines[VII]Development / forward-looking statements. Statements about enabling go/no-go decisions, accelerating timelines, “de-risking,” or resource optimization are forward-looking and based on preliminary findings. Actual results depend on future studies, regulatory feedback, and other factors. See “Forward-Looking Statements” below. by focusing resources only on effective therapies.
Clinically Proven. Scientifically Impressive.
Radiodiagnostics
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Meet the Mind Behind the Molecule
Benjamin Larimer, PhD
Co-founder and Chief Executive Officer
Umar Mahmood, MD, PhD
Co-founder
Eric P. Wehrenberg-Klee, MD
Co-founder
Colin Miller, PhD
Clinical Operations and Regulatory
Geoffrey Bilcer, PhD
Medicinal Chemistry
Ellen Cordo, CPA
CFO
Bob Gailus
Board Member
Riswanto Tan
Board Member
Prarthana Khanna
Board Member